



LJMU Research Online

Banach, M, Fronczek, M, Osadnik, T, Gach, A, Strapagiel, D, Słomka, M, Lejawa, M, Goc, A, Boniewska-Bernacka, E, Pańczyszyn, A, Lip, GYH, Toth, PP, Penson, PE and Józwiak, J

Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS) - study design and methodology

<http://researchonline.ljmu.ac.uk/id/eprint/24096/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Banach, M, Fronczek, M, Osadnik, T, Gach, A, Strapagiel, D, Słomka, M, Lejawa, M, Goc, A, Boniewska-Bernacka, E, Pańczyszyn, A, Lip, GYH, Toth, PP, Penson, PE and Józwiak, J (2024) Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the

LJMU has developed [LJMU Research Online](#) for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>

Risk of adverse cardiovascular events based on common genetic variants in 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS): study design and methodology

Maciej Banach^{1,2,3,4}, Martyna Fronczek⁵, Tadeusz Osadnik⁵, Agnieszka Gach⁶, Dominik Strapagiel⁷, Marcin Słomka⁷, Mateusz Lejawa⁵, Anna Goc⁸, Ewa Boniewska-Bernacka⁸, Anna Pańczyszyn⁸, Gregory Y.H. Lip^{9,10}, Dimitri P. Mikhailidis¹¹, Peter P. Toth^{3,12}, Peter E. Penson^{4,13}, Jacek Józwiak¹⁴

¹Department of Cardiology and Adult Congenital Heart Diseases, Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland

²Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland

³Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, USA

⁴Liverpool Centre for Cardiovascular Science (LCCS), Liverpool, UK

⁵Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

⁶Department of Genetics, Polish Mother's Memorial Hospital-Research Institute (PMMHRI), Lodz, Poland

⁷Biobank Lab, Department of Oncobiology and Epigenetics, Faculty of Biology and Environmental Protection, University of Lodz, Poland

⁸Institute of Medical Sciences, Department of Biology and Genetics, Faculty of Medicine, University of Opole, Poland

⁹Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University, and Liverpool Heart and Chest Hospital, Liverpool, UK

¹⁰Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

¹¹Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, UK

¹²Department of Preventive Cardiology, CGH Medical Center, Sterling, Illinois, USA

¹³Clinical Pharmacy & Therapeutics Research Group, School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK

¹⁴Department of Family Medicine and Public Health, Faculty of Medicine, University of Opole, Poland

Corresponding author:

Prof. Maciej Banach MD, PhD, FNLA, FAHA, FESC, FASA, Department of Preventive Cardiology and Lipidology Medical University of Lodz 281/289 Rzgowska St 93-338 Lodz, Poland
Phone: +48422711124
E-mail: maciej.banach@iczm.edu.pl

Submitted: 7 May 2024; Accepted: 8 August 2024

Online publication: 8 August 2024

Arch Med Sci

DOI: <https://doi.org/10.5114/aoms/192147>

Copyright © 2024 Termedia & Banach

Abstract

Introduction: Classical risk factors such as hypertension, hypercholesterolemia, pre-diabetes, diabetes and obesity can predict adverse cardiovascular events, but they are less prognostic in patients aged < 60 years. Polygenic risk scores (PRS) can be effective in predicting adverse coronary events in younger and middle-aged patients. Our main aim is to assess the utility of a new PRS created for the Polish population in predicting mortality during an 8-year follow-up in the nationwide LIPIDOGEN2015 population.

Material and methods: All DNA samples of 1779 patients were genotyped using Infinium Global Screening Array-24+ v3.0 Kit microarrays. The samples were amplified, fragmented, and hybridized to BeadChips. The BeadChips were scanned using iScan and converted to genotypes using Genome Studio 2.0.

Results: We will develop a PRS based on the identified single nucleotide polymorphisms (SNPs) in the LIPIDOGEN2015 project's studied population and determine the analyzed group's risk of death due to cardiovascular dis-

eases (CVD) based on data obtained from 8 years of patient-follow-up. Using the developed PRS scale and biochemical analyses, we will assess the effectiveness of lipid-lowering therapy with statins in patients with high and low genetic risk of sudden CVD events (secondary endpoints).

Conclusions: The developed PRS scale, combined with clinical covariates, will facilitate the creation of an algorithm to predict long-term mortality. This will enable us to stratify CVD risk more precisely, which may result in earlier implementation of lifestyle changes and dietary adjustments and potentially initiate earlier pharmacotherapy for at-risk individuals.

Key words: polygenic risk score, cardiovascular disease, risk factors.

Introduction

In affluent countries, atherosclerosis is the primary underlying cause of mortality and morbidity [1–3]. Coronary artery disease (CAD) accounts for 20% of all deaths in European Union countries and is the most common form of cardiovascular disease (CVD) [2, 3]. The available literature indicates that there is a lack of adequate public awareness regarding the relationship between CVD and atherosclerosis as the leading cause of mortality. Despite substantial medical, genetic, epidemiological, and preventive advancements in our understanding of atherogenesis during the past two decades, society's awareness of cardiometabolic diseases is still practically unaltered [3].

Risk scores derived from classical risk factors such as hypertension, hypercholesterolemia, prediabetes, diabetes, and cigarette smoking allow us to predict adverse CVD events to a certain degree. However, there are limitations in the current risk scores, especially when assessing younger patients [4–6]. This is because traditional risk factors and civilization diseases, unless concentrated and severe, require time to cause detrimental health impacts [7]. For example, using age as a stand-alone factor, with a cut-off value of 55 years, can be nearly as accurate as the Framingham Risk Score (FRS) in predicting cardiac events. This is equivalent to screening every 5 years in Framingham, with a 10-year risk cutoff of 8% [7]. Also, the risk score charts that are currently available are not very useful for routine risk assessment for the primary prevention of CAD [5]. Furthermore, genetic determinants of disease significantly influence risk in younger patients [8]. However, there is ongoing disagreement as to whether this is simply due to a genetic predisposition to CAD or a heightened genetic susceptibility to traditional risk factors, such as an unhealthy lifestyle. Thus, there is a need for novel methods to identify people who are at risk of developing CAD, including those based on advancements in basic scientific research [2].

For a long time, there have been efforts to evaluate genetic risk by identifying gene variants strongly linked to atherosclerotic cardiovascular

diseases (ASCVD) in gene-candidate investigations. Nevertheless, this method proved to be ineffective in forecasting the risk of CVD [9]. In 2007, Samani *et al.* published the first genome-wide association study (GWAS) on CAD. Since then, more than 150 gene loci related to CAD have been found [10]. Interestingly, most of these single nucleotide polymorphisms (SNPs) are found in genes not previously thought to be associated with atherosclerosis. Additionally, some are located in genes involved in lipid metabolism, insulin sensitivity, coagulation, inflammation, and vascular tone [11].

The polygenic risk score (PRS) is a weighted sum of the risk posed by multiple SNPs associated with the disease being analyzed [12]. To establish a PRS, the SNPs and their corresponding effect sizes, which quantify the association between the SNP and the disease, must be determined using an external GWAS-derived dataset. Next, we can verify the extensive correlation between SNPs across the genome using linkage disequilibrium [12]. Utilizing PRS based on these genetic variations has enhanced the accuracy of predicting cardiovascular events [13].

Statins are the primary therapy for lipid disorders and the most effective tool for preventing CAD in primary and secondary prevention [14]. In both primary and secondary prevention, the number needed to treat (NNT) for statins required to prevent one cardiovascular death is similar, between 15 and 30, and is comparable across different age groups [15]. Furthermore, the available data show that PRS can effectively predict the potential advantages of lipid-lowering therapy (LLT) [16]. Indeed, people with high genetic risk have a higher risk of subclinical atherosclerosis and benefit significantly more from statin treatment to prevent the first CVD event [2, 17, 18]. PRS may enable optimization of the NTT related to the use of statins for primary and secondary prevention of cardiovascular events [16, 17]. One recent study found that a PRS score derived from 27 SNPs accurately predicted adverse cardiovascular events and the magnitude of a response to treatment with a proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitor (evolocumab), compared with

a score derived from 6 million SNPs in people of European ancestry [18].

One important aspect to consider regarding the relevance of this 27-SNP score to the Polish population is that the above experiment included patients of European descent, and patients recruited from over 60 sites in Poland, Czechia, Slovakia, and Ukraine [19]. Improved identification of at-risk individuals, particularly among the youth, continues to be a critical public health concern. Early detection (the earlier, the better) of individuals who are at risk will facilitate prompt intervention, including education, lifestyle modifications, and LLT, all aimed at mitigating the mortality risk associated with cardiometabolic disorders [20].

It is worth noting that clinical risk estimators that are widely employed in Europe were initially developed for historical cohort studies involving middle-aged adults. As a result, their performance is comparatively inferior when applied to younger populations or individuals with non-European ancestry [21].

Hence, this study's main aim is to create a new PRS for the Polish population and assess its utility in predicting mortality during 8 years of follow-up in the nationwide LIPIDOGEN2015 population.

The secondary study goal is to assess the association between the lipid profile, statin/LLT treatment, and outcomes stratified by PRS score.

Material and methods

Subjects

Clinical and anthropometric data for each patient will be obtained from the nationwide cross-sectional study LIPIDOGRAM and LIPIDOGEN2015, conducted in 2015–2016 [22, 23]. In this program, a group of 438 physicians (investigators) working in 398 public or private primary health care ambulatory clinics in 16 central administrative regions of Poland (voivodeships) were selected (Figure 1).

The details of the LIPIDOGRAM and LIPIDOGEN2015 study have been described elsewhere [22]. Briefly, all consecutive individuals > 18 years old, who were under the care of a physician-investigator in a primary care clinic, voluntarily seeking medical assistance for any medical reason, were included. The exclusion criteria were diagnosed dementia or mental illness, which could lead to the inability to give informed consent or the patient's refusal to consent to participate in the study [22]. The LIPIDOGEN2015 project collected information




Figure 1. Study design and methodology aimed at determining the risk of adverse cardiovascular events based on the analysis of common genetic variants in an 8-year follow-up of the LIPIDOGEN2015 population using the polygenic risk score (PRS)

DNA – deoxyribonucleic acid, HDL-C – high-density lipoprotein cholesterol, LDL-C – low-density lipoprotein cholesterol, SNPs – single nucleotide polymorphisms, TC – total cholesterol, TG – triglycerides.

for each participant using personal questionnaires regarding chronic diseases and their treatment, lifestyle (diet, physical activity, smoking), CVD family history and demographic data such as age, gender, place of residence and level of education. All patients underwent anthropometric measurements (height, body weight, waist circumference, and hip circumference), blood pressure, heart rate, fasting glucose, and lipid profile samples that were taken on the day of patient's inclusion in the study. Study characteristics of patients participating in the LIPIDOGEN2015 study are presented in Table I.

Additionally, 2 ml of saliva was collected from each patient for DNA isolation and preservation for genetic analyses. Follow-up data on hospitalization and cardiovascular and cause-specific mortality, as well as all-cause mortality, will be collected in the given project to verify a minimum follow-up period of 8 years for every patient (Figure 1).

Genetic analyses

DNA samples were quantified using Quant-iT dsDNA Broad Range Assay Kits (Invitrogen, Carlsbad, CA, USA) and NanoDrop 2000 (Thermo Fisher Scientific Inc., Waltham, MA, USA) to determine DNA quality and concentration. The DNA samples' concentration was normalized to 50 ng/μl. DNA samples then underwent PCR reaction for sex verification [24]. All the DNA samples were genotyped

using Infinium Global Screening Array-24+ v3.0 Kit microarrays (Illumina, San Diego, CA, USA), according to the protocol provided by the manufacturer. Briefly, DNA samples were amplified, then enzymatically fragmented and hybridized to the BeadChips. Afterwards, the BeadChips underwent extension and X-staining processes. Next the BeadChips were scanned using iScan (Illumina Inc., San Diego, CA, USA). Microarrays' raw fluorescence intensity data were then converted to genotypes using Genome Studio 2.0. Standard microarray quality control protocols, such as filtering on sample call rates (> 0.94) or SNP genotyping rates (10% GenCall > 0.4) were executed. The results were exported from GenomeStudio using PLINK Input Report Plug-in v2.1.4 by forward strand. Genetic data were filtered; thus only variants with minor allele frequencies above 5% were included. Subsequently, Hardy-Weinberg equilibrium was tested and SNPs with a *p*-value > 0.05 were excluded from the association analysis. Information on the selected SNPs is presented in Table II.

Statistical analysis

Patients will be stratified by their genetic risk score into quintiles. Similarly to other studies on this issue, the lowest genetic risk will be defined as quintile 1, the highest as quintile 5. Quintiles 2-4 will be described as intermediate genetic risk [17, 18]. Continuous variables will be compared using the Wilcoxon rank sum test. Additionally, the Jonckheere-Terpstra test for a trend and Cochran-Armitage or similar tests for trends will be used to evaluate changes in continuous variables and proportions across groups stratified by genetic risk score. If the assumptions of hazard proportionality are confirmed, Cox proportional hazard regression will be carried out to assess the association between quantiles of PRS, as well as standardized PRS and major adverse events defined as death, myocardial infarction, and stroke. The analysis will be adjusted for clinical variables. A *p*-value of < 0.05 will be considered statistically significant. A sample of 1779 persons is sufficient to detect a significant (at $\alpha = 0.05$) association between the 27-SNP PRS and the occurrence of CAD with a power of 81.9%. Calculations were performed under conservative settings – the prevalence of CAD was assumed to be 5%, and the proportion of variance explained by genetic effects was assumed to be 0.011.

Results

Commonly occurring genetic variants listed in Table II will be correlated with outcomes. We intend to develop a preventive model based on the detailed clinical variables of patients from the LIPIDOGEN2015 study and the outcomes of SNP

Table I. Clinical characteristics of the LIPIDOGEN2015 study sample (*N* = 1779)

Variable	<i>n</i> [%] or mean ± SD
Age [years]	51.2 ±13.0
Males	710 (39.9)
Central obesity	887 (49.9)
Waist circumference [cm]	94.02 ±14.25
Body mass index [kg/m ²]	28.2 ±5.1
Hypertension	765 (43.0)
Diabetes mellitus	287 (16.1)
Dyslipidemia	889 (50)
Coronary artery disease	184 (10.3)
Physically active	779 (43.8)
Total cholesterol [mg/dl]	206.7 ±45.2
LDL-C [mg/dl]	131.5 ±42.03
HDL-C [mg/dl]	55.03 ±15.9
TG [mg/dl]	158.8 ±141.3
Glucose [mg/dl]	104.5 ±27.1
HbA _{1c} (%)	5.71 ±0.97

LDL-C – low-density lipoprotein cholesterol, HDL-C – high-density lipoprotein cholesterol, TG – triglycerides, HbA_{1c} – glycated hemoglobin A_{1c}.

genotyping analyses utilizing DNA microarrays. The PRS created for the Polish population will estimate an individual's genetic susceptibility to a specific trait or disease. We will select as features the conventional risk factors for CAD already included in several widely used risk scales, for which data are available. We will include additional non-genetic attributes such as diet, medications, and lifestyle factors to improve the model's performance. Using a logistic regression framework, we will generate different risk prediction models, each with a different subset of features.

Discussion

ASCVD is classified as the main cause of loss of life years (LLY) due to disability or premature death among adults [1, 25]. GWAS studies do not fully elucidate the causal mechanisms of CVD. Further stratification of the genetic risk of developing CVD events will enable easier access to health care for patients with increased risk of cardiometabolic diseases and their complications [26]. This will enable initiation of early preventive measures to avoid loss of full-fledged functioning in every-

Table II. List of polymorphisms that will serve to calculate a polygenic risk score

No.	Gene	rs number	Chromosome region	Genome position (GRCh38.p14) (NC_000001.11)
1.	<i>PCSK9</i>	rs11206510	1p32.3	55030366
2.	<i>PLPP3</i>	rs17114036	1p32.2	56497149
3.	<i>CELSR2</i>	rs646776	1p13.3	109275908
4.	<i>MIA3</i>	rs17465637	1q41	222650187
5.	<i>WDR12</i>	rs6725887	2q33.1	202881162
6.	<i>MRAS</i>	rs9818870	3q22.3	138403280
7.	<i>PHACTR1</i>	rs9349379	6p24.1	12903725
8.	<i>ANKS1A</i>	rs17609940	6p21.31	35067023
9.	<i>TCF21</i>	rs12190287	6q23.2	133893387
10.	<i>LPA</i>	rs3798220	6q25.3	160540105
11.	<i>LPA</i>	rs10455872	6q25.3	160589086
12.	<i>ZC3HC1</i>	rs11556924	7q32.2	130023656
13.	<i>CDKN2B-AS1</i>	rs4977574	9p21.3	22098575
14.	<i>ABO</i>	rs635634	9q34.2	133279427
15.	<i>CXCL12</i>	rs1746048	10q11.21	44280376
16.	<i>CNNM2</i>	rs12413409	10q24.32	102959339
17.	<i>ZPR1</i>	rs964184	11q23.3	116778201
18.	<i>SH2B3</i>	rs3184504	12q24.12	111446804
19.	<i>HNF1A</i>	rs2259816	12q24	120997784
20.	<i>COL4A1</i>	rs4773144	13q34	110308365
21.	<i>HHIPL1</i>	rs2895811	14q32.2	99667605
22.	<i>ADAMTS7</i>	rs3825807	15q25.1	78796769
23.	<i>SMG6</i>	rs216172	17p13.3	2223210
24.	<i>RASD1</i>	rs12936587	17p11.2	17640408
25.	<i>UBE2Z</i>	rs46522	17q21.32	48911235
26.	<i>SMARCA4</i>	rs1122608	19p13.2	11052925
27.	<i>KCNE2</i>	rs9982601	21q22.11	34226827

PCSK9 – proprotein convertase subtilisin/kexin 9, *PLPP3* – phospholipid phosphatase 3, *CELSR2* – cadherin EGF LAG seven-pass G-type receptor 2, *2MIA3* – melanoma inhibitory activity member 3, *WDR12* – WD repeat domain 12, *MRAS* – muscle RAS oncogene homolog, *PHACTR1* – phosphatase and actin regulator 1, *ANKS1A* – ankyrin repeat and SAM domain-containing protein 1A, *TCF21* – transcription factor 21, *LPA* – lipoprotein(A), *ZC3HC1* – zinc finger C3HC-type containing 1, *CDKN2B-AS1* – cyclin dependent kinase inhibitor 2B antisense RNA 1, *ABO* – alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase, *CXCL12* – C-X-C motif chemokine ligand 12, *CNNM2* – cyclin and CBS domain divalent metal cation transport mediator 2, *ZPR1* – ZPR1 zinc finger, *SH2B3* – SH2B adaptor protein 3, *HNF1A* – hepatocyte nuclear factor 1 homeobox A, *COL4A1* – collagen type IV alpha 1 chain, *HHIPL1* – hedgehog interacting protein-like 1, *ADAMTS7* – ADAM metalloproteinase with thrombospondin type 1 motif 7, *SMG6* – SMG6 nonsense mediated mRNA decay factor, *RASD1* – Ras related dexamethasone induced 1, *UBE2Z* – ubiquitin conjugating enzyme E2Z, *SMARCA4* – SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4, *KCNE2* – potassium voltage-gated channel subfamily E regulatory subunit 2.

day life and to prevent premature death due to CVD events [26]. The extended latency period of CAD allows for early implementation of preventive measures; however, it also necessitates the identification of patients at CVD risk during the asymptomatic phase [26]. Risk scales that are derived from traditional risk factors, including Framingham [27], SCORE [28], PROCAM [29], Reynolds [30], the more recent SCORE-2 and SCORE-OP, which were included in the European Society of Cardiology (ESC) Prevention guidelines 2021 [31], and the most recent SCORE2-Diabetes [32], are to some degree effective in identifying patients who are at CVD risk. The Pol-SCORE scale was developed for the Polish population in 2015 and was used to assess the risk of death from cardiovascular causes within 10 years, including very elderly patients (> 65 years of age) [33].

Nevertheless, the utility of these scores is significantly diminished when applied to patients younger than 55 [31]. Most frequently administered in the United States to patients younger than 40, the Framingham Risk Score as a tool for identifying high-risk individuals is ineffective [34]. The SCORE risk scale (as well as SCORE2), widely utilized in Europe, is also limited to patients 40 or older. Furthermore, it has deficiencies in identifying high-risk patients in the youngest age categories [35]. As previously stated, this phenomenon can likely be attributed to the gradual accumulation of detrimental effects caused by diabetes, hypercholesterolemia (excluding familial hypercholesterolemia [FH]), obesity, and unhealthy behaviors such as smoking [23, 36, 37].

The risk of premature CAD (defined as age 55 or younger in men and 60/65 or younger in women) is influenced more by genetics than by environmental factors [38]. The prevalence of CAD among patients under 60 is 5.9% for women and 6.3% for men, although more recently, especially in the post-COVID19 period, it has increased to as high as 10–15% in some countries [25, 39]. In the case of premature CAD, the subclinical atherosclerosis process likely begins 10–20 years earlier. Additionally, there is a positive correlation between age and the pathophysiology of atherosclerosis [40].

A method for accumulating data on genetic variants associated with specific disease traits is known as PRS [38, 41]. GWAS establish the association between gene variants and specific diseases. PRS may capture an increased genetic risk of a particular disease, based on numerous frequently occurring variants, in accordance with the principle “common disease – common variant” [38], as GWAS methodology typically identifies only variants that occur with a frequency greater than 5%. More than 150 gene loci have been identified as being associated with CAD [41]. These loci have achieved an accepted significance level of less

than 5×10^{-8} in studies that have tested millions of gene variants multiple times [41].

Therefore, if the PRS for a particular disease trait is validated for the population, it may be possible to reliably locate each individual's risk on the genetic risk scale of developing a certain disease or its complications. Prior PRS associated with CAD were determined by aggregating the number of disease-related variants, irrespective of the degree of association with the disease trait underlying the condition [42]. At this time, variants are weighted according to the severity of their association with the disease trait as a result of data collection, and several methods exist for accomplishing this [43]. Also, the establishment of population biobanks containing accessible clinical data makes this much more feasible.

As a result, PRS is currently more dependable than when the concept of genetic risk estimation was first conceived. Theoretically, PRS could identify patients at risk for CAD earlier in life, even as early as after birth; this would significantly alter the approach to primary (primordial) prevention of atherosclerotic diseases [44]. Assuming a liability threshold model, in which CAD manifests itself upon reaching a particular risk threshold in a continuous polygenic score distribution, risk prediction is frequently modelled using the PRS. This continuous measure is normally distributed in the population. However, the PRS score may be a risk indicator, but is not a diagnostic test for CAD. It should be evaluated like other continuously monitored conventional risk factors, including systolic blood pressure and LDL cholesterol [45]. For example, the PRS model for CAD constructed by Busby *et al.* included 29,389 individuals from various cohorts and genetic origin groups. This model classified 12–24% of individuals as having high genetic risk. Reclassifying borderline or intermediate 10-year risk of ASCVD using this risk factor improved the assessment of both CAD and ASCVD (net reclassification improvement [NRI] = 13.14% [95% CI: 9.23–17.06%] and NRI = 10.70% [95% CI: 7.35–14.05], respectively) in 9691 individuals [46]. According to these analyses, utilizing genetic information in PRS as risk enhancers improves ASCVD risk assessment, defining a strategy for managing ASCVD prevention [47]. Isgut *et al.* conducted research to validate the clinical utility of incorporating four PRS derived from SNPs (194, 46K, 1.5M, and 6M) in conjunction with conventional risk factors for predicting myocardial infarction (MI), ischemic heart disease (IHD), and premature MI occurrence before the age of 50 years [48]. They confirmed that clinical and lifestyle factors, not independent of genetic susceptibility, contribute to the increased risk of CVD in middle-aged individuals, and indicated that polygenic risk assessment may be useful for predicting risk at birth

when other risk factors are unknown, thereby identifying individuals most susceptible to developing heart disease [48].

Over the past 5 years, extensive data on PRS and the incidence of CVD have been published. The PRS employed in those investigations ranged from 27 to more than 6 million SNPs. Based on data from primary prevention trials such as JUPITER (*Justification for the Use of Statin in Prevention: An Intervention Trial Evaluating Rosuvastatin*), ASCOT (*Anglo-Scandinavian Cardiac Outcomes Trial*), and the secondary prevention trials CARE (*Cholesterol and Recurrent Events*) and PROVE-IT TIMI 22 (*Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22*), Mega *et al.* investigated the PRS score based on 27 SNPs [17]. The authors demonstrated the potential utility of this score in predicting initial and recurrent cardiovascular events and its potential function in predicting response to statin therapy [17]. In the post-hoc analysis of the FOURIER (*Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk*), a 27-SNP risk score was equivalent to a 6 million SNP risk score in terms of the incidence of severe vascular and coronary events [18]. The 27-SNP score and the 6 million risk score were independently associated with the risk of major coronary and vascular events, even after adjusting for multiple clinical factors. Those individuals whose 27-SNP risk score indicated a high genetic risk had a 1.65-fold increased hazard for major coronary events and a 1.37-fold increased hazard for major vascular events. Conversely, those whose genetic risk was intermediate had a 1.23-fold increased hazard for major coronary events and a 1.14-fold increased hazard for major vascular events [18]. The authors reported comparable results for individuals with high and intermediate genetic risk, as determined by the 6 million SNP score, whereby those classified as having a high genetic risk were associated with a 1.55-fold increased risk of major coronary events and a 1.31-fold increased risk of major vascular events, respectively [18]. Conversely, those classified as having an intermediate genetic risk were associated with 1.26-fold and 1.11-fold increased risk of major vascular events and major coronary events, respectively. Consequently, the 27-SNP score was equivalent to a 6 million SNP score in risk prediction [18].

To our best knowledge, this will be the first study examining the association between the PRS and CAD in the Polish population. The purpose of the LIPIDOGEN2015 study was to assess genetic risk factors associated with CAD and conditions that cause atherosclerosis. The LIPIDOGEN2015 population is distinctive in that it is representative of the Polish population in a primary care context,

owing to its meticulous design. We are confident that by validating this PRS in the LIPIDOGEN2015 population, additional research can be conducted to examine the score's applicability to other cohorts. Our study may also justify planning additional research, particularly randomized clinical trials (RCTs), in which patients are randomly assigned to receive pharmacological treatment for the prevention of CAD according to a PRS score adjustment for clinical variables. PRS stratification (together with/without the coronary artery calcium (CAC) score, currently increasingly being used [47, 49]) may help decide whether to start pharmacotherapy with statins.

In primary and secondary prevention, statins are the most effective therapy for reducing cholesterol levels and preventing CAD. Comparable across age groups, the quantity of statins necessary to avert a single cardiovascular death is equivalent in both primary and secondary prevention [15]. In addition, empirical studies have shown that PRS is a reliable method for predicting the prospective benefits of cholesterol-lowering drugs [16]. Klarin *et al.* propose that statins should be taken by people whose risk of developing ASCVD within 10 years is estimated at 5.0–19.9%. As an adjunct to conventional clinical risk assessments, PRS for CAD should be considered to be used in statin allocation. In epidemiological and clinical cohorts, high PRS for CAD is associated with incident events similar to most other risk factors [50].

In conclusion, the PRS scale developed for the Polish population, combined with clinical covariates, will facilitate the creation of an algorithm to predict long-term mortality. This will enable the earlier implementation of lifestyle changes and dietary adjustments and potentially initiate earlier pharmacotherapy for at-risk individuals. It is critically important especially in the high CVD risk population of Poland, with 80,000 MIs and 160,000 deaths due to cardiovascular disease annually, with only 24% of patients being on LDL-C goal, and less than 20% for those at very high CVD risk [51–55].

Acknowledgments

We would like to thank all the volunteers of LIPIDOGRAM 2015 and investigators, all volunteer staff, and all participants.

Funding

The study has been financed from the OPUS grant of the National Centre of Science (NCS) in Poland entitled “Polygenic Risk Scale – calculation of the risk of adverse cardiovascular events, based on common genetic variants in the 8-year follow-up of the LIPIDOGEN2015 population” (2021/43/B/NZ5/01641; PI: Prof. Maciej Banach).

Ethical approval

The National Science Centre (Grant No. UMO-2021/43/B/NZ5/01641, within the call OPUS 22) financed the study, which is being conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. The Bioethical Commission of the Chamber of Physicians approved the study protocol on 02/12/2015 (Resolution No. K.B.Cz.-0018/2015) [23]. All individuals signed an informed consent form to participate in the study and gave their permission to use anonymous questionnaire data, laboratory test results, and secure biological material for statistical and scientific studies.

Conflict of interest

The authors declare no conflict of interest.

References

1. Mensah GA, Fuster V, Murray CJL, Roth GA; Global Burden of Cardiovascular Diseases and Risks Collaborators. Global burden of cardiovascular diseases and risks, 1990-2022. *J Am Coll Cardiol* 2023; 82: 2350-473.
2. Natarajan P, Young R, Stitzel NO, et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. *Circulation* 2017; 135: 2091-101.
3. Daponte-Codina A, Knox EC, Mateo-Rodriguez I, et al. Gender and social inequalities in awareness of coronary artery disease in European countries. *Int J Environ Res Public Health* 2022; 19: 1388.
4. Sundquist K, Winkleby M, Li X, Ji J, Hemminki K, Sundquist J. Familial [corrected] transmission of coronary heart disease: a cohort study of 80,214 Swedish adoptees linked to their biological and adoptive parents. *Am Heart J* 2011; 162: 317-23.
5. Studziński K, Tomasik T, Krzysztoń J, Józwiak J, Windak A. Effect of using cardiovascular risk scoring in routine risk assessment in primary prevention of cardiovascular disease: an overview of systematic reviews. *BMC Cardiovasc Disord* 2019; 19: 11.
6. Banach M, Osadnik T, Lejawa M, Golawski M, Gierlotka M, Jozwiak J. Development and validation of risk score for patients in primary care setting in Poland. *Eur Heart J* 2023; 44 (Suppl 2): ehad655.2439.
7. Wald NJ, Simmonds M, Morris JK. Screening for future cardiovascular disease using age alone compared with multiple risk factors and age. *PLoS One* 2011; 6: e18742.
8. Erdmann J, Schunkert H. Genetics of (premature) coronary artery disease. In: *Clinical Cardiogenetics*. Baars HF, Doevendans FM, Houweling AC, van Tintelen JP (eds.). 3rd ed. Springer 2020; 413-30.
9. Hengstenberg C, Bröckel U, Holmer S, et al. Genetic factors in myocardial infarction-results from a candidate gene and a genome-wide approach between beta blockers. *Herz* 2002; 27: 649-61.
10. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. *N Engl J Med* 2007; 357: 443-53.
11. Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. *Nat Rev Genet* 2017; 18: 331-44.
12. Jiang W, Chen L, Girgenti MJ, Zhao H. Tuning parameters for polygenic risk score methods using GWAS summary statistics from training data. *Nat Commun* 2024; 15: 24.
13. Levin MG, Rader DJ. Polygenic risk scores and coronary artery disease: ready for prime time? *Circulation* 2020; 141: 637-40.
14. Banach M, Surma S. A look to the past — what has had the biggest impact on lipids in the last four decades? A personal perspective. *Arch Med Sci* 2023; 19: 559-64.
15. Armitage J, Baigent C, Barnes E, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet* 2019; 393: 407-15.
16. Arnold N, Koenig W. Polygenic risk score: clinically useful tool for prediction of cardiovascular disease and benefit from lipid-lowering therapy? *Cardiovasc Drugs Ther* 2021; 35: 627-35.
17. Mega JL, Stitzel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy. *Lancet* 2015; 385: 2264.
18. Marston NA, Kamanu FK, Nordio F, et al. Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: results from the FOURIER Trial. *Circulation* 2020; 141: 616-23.
19. Evolocumab in Dyslipidemia – Clinical Trials Registry - ICH GCP n.d. <https://ichgcp.net/clinical-trials-registry/NCT02867813> (accessed May 8, 2024).
20. Banach M, Reiner Z, Cicero AFG, et al. 2022: the year in cardiovascular disease – the year of upfront lipid lowering combination therapy. *Arch Med Sci* 2022; 18: 1429-34.
21. Patel AP, Wang M, Ruan Y, et al. A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease. *Nat Med* 2023; 29: 1793-803.
22. Józwiak JJ, Kasperczyk S, Tomasik T, et al. Design and rationale of a nationwide screening analysis from the LIPIDOGram2015 and LIPIDOGram2015 studies. *Arch Med Sci* 2022; 18: 604-16.
23. Józwiak JJ, Studziński K, Tomasik T, et al. The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGram2015 study. *Atheroscler Suppl* 2020; 42: e15-24.
24. Strapagiel D, Majewska M, Janik K, Sobalska M, Bartosz G. Method for gender determination. *PL232652B1* 2019.
25. Banach M, Surma S. Monitoring of traditional atherosclerosis cardiovascular disease risk factors – is it enough to prevent premature acute coronary syndrome? *Lancet Reg Health Eur* 2024; 38: 100866.
26. O'Sullivan JW, Raghavan S, Marquez-Luna C, et al. Polygenic risk scores for cardiovascular disease: a scientific statement from the American Heart Association. *Circulation* 2022; 146: e93-118.
27. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation* 2008; 117: 743-53.
28. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J* 2003; 24: 987-1003.
29. Assmann G, Schulte H, Cullen P, Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. *Eur J Clin Invest* 2007; 37: 925-32.
30. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. *JAMA* 2007; 297: 611-9.

31. Visseren F, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). *Eur Heart J* 2021; 42: 3227-337.
32. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. *Eur Heart J* 2023; 44: 2544-56.
33. Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPIP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. *Arch Med Sci* 2021; 17: 1447-547.
34. Berry JD, Lloyd-Jones DM, Garside DB, Greenland P. Framingham risk score and prediction of coronary heart disease death in young men. *Am Heart J* 2007; 154: 80-6.
35. Elosua R. Cardiovascular risk functions: usefulness and limitations. *Rev Esp Cardiol (Engl Ed)* 2014; 67: 77-9.
36. Labuz-Roszak B, Banach M, Skrzypek M, et al. Secondary stroke prevention in Polish adults: results from the LIPIDOGEM2015 Study. *J Clin Med* 2021; 10: 4472.
37. Studziński K, Tomasiak T, Windak A, et al. The differences in the prevalence of cardiovascular disease, its risk factors, and achievement of therapeutic goals among urban and rural primary care patients in Poland: results from the LIPIDOGEM 2015 study. *J Clin Med* 2021; 10: 5656.
38. Forgetta V, Manousaki D, Istomine R, et al. Rare genetic variants of large effect influence risk of type 1 diabetes. *Diabetes* 2020; 69: 784-95.
39. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. *Circulation* 2015; 131: e29-39.
40. Knoflach M, Kiechl S, Penz D, et al. Cardiovascular risk factors and atherosclerosis in young women: atherosclerosis risk factors in female youngsters (ARFY study). *Stroke* 2009; 40: 1063-9.
41. Musunuru K, Kathiresan S. Genetics of common, complex coronary artery disease. *Cell* 2019; 177: 132-45.
42. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. *Cell* 2012; 148: 1242-57.
43. Rotter JJ, Lin HJ. An outbreak of polygenic scores for coronary artery disease. *J Am Coll Cardiol* 2020; 75: 2781-4.
44. Inouye M, Abraham G, Nelson CP, et al. Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention. *J Am Coll Cardiol* 2018; 72: 1883-93.
45. Fahed AC, Natarajan P. Clinical applications of polygenic risk score for coronary artery disease through the life course. *Atherosclerosis* 2023; 386: 117356.
46. Busby GB, Kulm S, Bolli A, Kintzle J, Domenico P Di, Bottà G. Ancestry-specific polygenic risk scores are risk enhancers for clinical cardiovascular disease assessments. *Nat Commun* 2023; 14: 7105.
47. Banach M, Surma S, Guzik T, Penson PE, Blaha MJ, Sperling SS. Upfront lipid-lowering combination therapy in patients at very high cardiovascular risk – time to stop debate and start effective prevention. *Cardiovasc Res* 2024 (in press).
48. Isgut M, Sun J, Quyyumi AA, Gibson G. Highly elevated polygenic risk scores are better predictors of myocardial infarction risk early in life than later. *Genome Med* 2021; 13: 13.
49. Osei AD, Mirbolouk M, Berman D, et al. Prognostic value of coronary artery calcium score, area, and density among individuals on statin therapy vs. non-users: the coronary artery calcium consortium. *Atherosclerosis* 2021; 316: 79-83.
50. Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. *Nat Rev Cardiol* 2022; 19: 291-301.
51. Banach M, Kaźmierczak J, Mitkowski P, et al. Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts' opinion. The compromise between EBM and possibilities in health-care. *Arch Med Sci* 2022; 18: 569-76.
52. Banach M, Surma S, Kapton-Cieślicka A, et al. Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association. *Arch Med Sci* 2024; 20: 28-42.
53. Mitkowski P, Witkowski A, Stępińska J, et al. Position of the Polish Cardiac Society on therapeutic targets for LDL cholesterol concentrations in secondary prevention of myocardial infarctions. *Kardiologia* 2023; 81: 818-23.
54. Banach M, Surma S, Toth PP, endorsed by the International Lipid Expert Panel (ILEP). 2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024? *Arch Med Sci* 2023; 19:1602-15.
55. Sheth S, Banach M, Toth PP. Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now? *Expert Rev Cardiovasc Ther* 2024; 22: 441-57.